Novelties in the treatment of community-acquired and hospital-acquired pneumonia
Abstract
Pneumonia remains a leading cause of morbidity and mortality worldwide, placing a significant burden on healthcare systems due to hospitalizations and the demand for medical resources.In recent years, new drugs have been developed to improve the effectiveness and safety of empirical treatment for community-acquired pneumonia and both empirical and targeted treatments for hospital-acquired and ventilator-associated pneumonia, including those caused by highly antibiotic-resistant pathogens.The aim of this narrative review is to focus on recently approved drugs for pneumonia and provide an overview of promising future therapeutic options.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.